WO2007029267A1 - Procédé de préparation industriellement viable du chlorhydrate d'imidapril - Google Patents
Procédé de préparation industriellement viable du chlorhydrate d'imidapril Download PDFInfo
- Publication number
- WO2007029267A1 WO2007029267A1 PCT/IN2006/000183 IN2006000183W WO2007029267A1 WO 2007029267 A1 WO2007029267 A1 WO 2007029267A1 IN 2006000183 W IN2006000183 W IN 2006000183W WO 2007029267 A1 WO2007029267 A1 WO 2007029267A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- product
- acid
- hydrochloride
- methyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 21
- 229960003409 imidapril hydrochloride Drugs 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 title claims abstract description 8
- 230000008569 process Effects 0.000 title claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- GFZFELCFSBCPDB-AAEUAGOBSA-N ethyl (2s)-2-[(4s)-4-methyl-2,5-dioxo-1,3-oxazolidin-3-yl]-4-phenylbutanoate Chemical compound C([C@@H](C(=O)OCC)N1C(OC(=O)[C@@H]1C)=O)CC1=CC=CC=C1 GFZFELCFSBCPDB-AAEUAGOBSA-N 0.000 claims abstract description 3
- 230000001476 alcoholic effect Effects 0.000 claims abstract 4
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 2
- -1 inorganic acid salts Chemical class 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000002585 base Substances 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910000287 alkaline earth metal oxide Inorganic materials 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 238000006264 debenzylation reaction Methods 0.000 claims 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000006408 oxalic acid Nutrition 0.000 claims 1
- 238000005897 peptide coupling reaction Methods 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- LSLQGMMMRMDXHN-GEUPQXMHSA-N Imidapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 LSLQGMMMRMDXHN-GEUPQXMHSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 229960001195 imidapril Drugs 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- WFLQXECQLHZKMV-NSHDSACASA-N ethyl (2s)-2-amino-4-phenylbutanoate Chemical compound CCOC(=O)[C@@H](N)CCC1=CC=CC=C1 WFLQXECQLHZKMV-NSHDSACASA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 2
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QXYOROBKCZWFKK-UHFFFAOYSA-N 2-(4-methylphenyl)sulfonyloxypropanoic acid Chemical compound OC(=O)C(C)OS(=O)(=O)C1=CC=C(C)C=C1 QXYOROBKCZWFKK-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- LJPCNSSTRWGCMZ-UHFFFAOYSA-N 3-methyloxolane Chemical compound CC1CCOC1 LJPCNSSTRWGCMZ-UHFFFAOYSA-N 0.000 description 1
- AGEUQNZXCIVHPB-UHFFFAOYSA-N 4-(hydroxyamino)-4-oxobutanoic acid Chemical compound ONC(=O)CCC(O)=O AGEUQNZXCIVHPB-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- LPHRTQQOKYRTQS-UHFFFAOYSA-N NC(=O)C([SiH3])[SiH3] Chemical compound NC(=O)C([SiH3])[SiH3] LPHRTQQOKYRTQS-UHFFFAOYSA-N 0.000 description 1
- 229910018954 NaNH2 Inorganic materials 0.000 description 1
- WWISPHBAYBECQZ-UHFFFAOYSA-N Pyrazine, 3,6-dihydro-3,6-dimethyl-2,5-dihydroxy- Chemical compound CC1NC(=O)C(C)NC1=O WWISPHBAYBECQZ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical compound [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- AGWNCRTUZAZYKJ-HDHUNYPFSA-N tert-butyl (4s)-3-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylate;hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(=O)OC(C)(C)C)=O)CC1=CC=CC=C1 AGWNCRTUZAZYKJ-HDHUNYPFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
Definitions
- the invention relates to a novel method for the preparation of imidapril hydrochloride of formula I
- the chemical entity (4S)-3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3- phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid hydrochloride of formula I belongs to a group of medicines called ACE inhibitors, which block the action of a chemical in the body called angiotensin converting enzyme (ACE). Normally ACE produces another chemical, angiotensin II. Thus imidapril reduces the amount of angiotensin Il in the blood. Angiotensin Il has two actions.
- EP 95163/US4508727 discloses synthesis of imidapril hydrochloride of formula employing several stages. This is shown in the following schemes IA and IB
- ECPP alanine of formula-Ilia is activated with N- hyroxysuccinicimide using dicyclohexylcarbodiimide and the activated ester is coupled with t-butyl imidaozlinone-4-carboxylate of formula-ll a in the presence of potassium tert. butoxide to give a dipeptide of formula-V, which is converted to the product of formula-l by treatment with dioxane-HCI
- the scheme I B describes a methodology, which is similar to the one described in scheme IA, except the fact that benzyl imidazolidinone-4-carboxylate of formula-l I b is used instead of the t-butyl ester Ha.
- the coupled product of formula-VI is debenzylated using Pd/C - H 2 and treated with dioxane-HCI to get the product of formula-l.
- the present invention provides a novel process for the preparation of imidapril of formula I by reacting esters of 4(S)-1-methyl-2-oxoimidazolidine-4-carboxylate of formula-ll with (S)-ethyl-2-[(S)-4-methyl-2,5-dioxooxazolidin-3-yl]-4-phenylbutanoate of formula-Ill in presence of a base like sodium hydride/sodium methoxide, potassium tert. butoxide etc. After the coupling, the protecting group was removed by means of catalytic hydrogenation or hydrolysis to get the required compound
- the reaction of the product of formula-Ill with imidazolidinone-4-carboxylicacid of formula-ll was tried using different bases viz., NaH, NaOBu', KOBu 1 , NaNH 2 etc. It was preferable to use NaH, Na/KOBu 1 . It was more preferable to use Na/KOBu 1 .
- the reaction was studied in different solvents like dichloroethane, dichloromethane, acetonitrile, tetrahydrofuran, 2 or 3 methyl tetrahydrofuran, 1,4-dioxane, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone, dimethylsulfoxide, sulfolane etc.
- esters of 4(S)-1-methyl-2-oxoimidazolidine-4- carboxylate of formula-ll with (S)-ethyl-2-[(S)-4-methyl-2,5-dioxooxazolidin ⁇ 3-yl]-4- phenylbutanoate of formula-Ill can be prepared conventionally by well known methods.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne un procédé innovant de préparation de chlorhydrate d'imidapril de formule (I). Selon ledit procédé, on fait réagir des esters de 4-carboxylate de 4(S)-1-méthyl-2-oxoimidazolidine de formule (II) avec du 4-phénylbutanoate de (S)-éthyl-2-[(S)-4-méthyl-2,5-dioxooxazolidin-3-yl] de formule (III) et on hydrolyse le produit couplé avec un chlorhydrate alcoolique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1247CH2005 | 2005-09-06 | ||
IN1247/CHE/2005 | 2005-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007029267A1 true WO2007029267A1 (fr) | 2007-03-15 |
Family
ID=37835419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2006/000183 WO2007029267A1 (fr) | 2005-09-06 | 2006-05-29 | Procédé de préparation industriellement viable du chlorhydrate d'imidapril |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007029267A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104119424A (zh) * | 2014-07-01 | 2014-10-29 | 上海天慈生物谷生物工程有限公司 | (4s)-3-[(2s)-2[(1s)-1-乙氧羰基-3-苯丙基]氨基丙酰基]-1-甲基-2-氧代咪唑啉-4-羧酸的制备方法 |
CN111253315A (zh) * | 2020-03-10 | 2020-06-09 | 北京阳光诺和药物研究有限公司 | 盐酸咪达普利有机杂质及其制备方法 |
CN113024632A (zh) * | 2021-03-28 | 2021-06-25 | 山东中健康桥制药有限公司 | 一种盐酸咪达普利的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541635B1 (en) * | 2002-03-29 | 2003-04-01 | Everlight Usa, Inc. | Method for producing angiotensin converting enzyme inhibitor |
-
2006
- 2006-05-29 WO PCT/IN2006/000183 patent/WO2007029267A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541635B1 (en) * | 2002-03-29 | 2003-04-01 | Everlight Usa, Inc. | Method for producing angiotensin converting enzyme inhibitor |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104119424A (zh) * | 2014-07-01 | 2014-10-29 | 上海天慈生物谷生物工程有限公司 | (4s)-3-[(2s)-2[(1s)-1-乙氧羰基-3-苯丙基]氨基丙酰基]-1-甲基-2-氧代咪唑啉-4-羧酸的制备方法 |
CN104119424B (zh) * | 2014-07-01 | 2018-12-18 | 上海天慈生物谷生物工程有限公司 | (4s)-3-[(2s)-2[(1s)-1-乙氧羰基-3-苯丙基]氨基丙酰基]-1-甲基-2-氧代咪唑啉-4-羧酸的制备方法 |
CN111253315A (zh) * | 2020-03-10 | 2020-06-09 | 北京阳光诺和药物研究有限公司 | 盐酸咪达普利有机杂质及其制备方法 |
CN113024632A (zh) * | 2021-03-28 | 2021-06-25 | 山东中健康桥制药有限公司 | 一种盐酸咪达普利的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20050113292A (ko) | 광학적으로 순수한 4-하이드록시-2-옥소-1-피롤리딘아세트아미드의 제조방법 | |
EP2121605B1 (fr) | Procédé de préparation du (1r,2s,5s)-n-[(1s)-3-amino-1-(cyclobutylméthyl)-2,3-dioxopropryl]-3-[(2s)-2-[[[(1,1-diméthyléthyl)amino]-carbonyl]amino]-3,3-diméthyl-1-oxobutyl]-6,6-diméthyl-3-azabicyclo[3.1.0]hexane-2-carboxamide | |
JPH07304770A (ja) | 新規ベンゾアゼピノン誘導体 | |
WO2007029267A1 (fr) | Procédé de préparation industriellement viable du chlorhydrate d'imidapril | |
US6818788B2 (en) | Method for synthesis of n-[(s)-1-carboxybutyl]-(s)-alanine esters and use in synthesis of perindopril | |
WO2011156355A1 (fr) | Procédé de production de sels de phénylguanidine et de leurs intermédiaires | |
US6541635B1 (en) | Method for producing angiotensin converting enzyme inhibitor | |
CN100395264C (zh) | 合成培哚普利及其药学上可接受盐的新方法 | |
WO2009098251A1 (fr) | Nouveaux dérivés de cycloalcanonealanine β-substituée | |
KR100766578B1 (ko) | 레바미피드의 제조방법 | |
JP2005501028A (ja) | ベナゼプリル及びその類似体の生産に有用な中間体の速度論的分離 | |
US6610855B2 (en) | Synthesis of 3-amino-3-aryl propanoates | |
KR100880623B1 (ko) | 발사르탄의 제조방법 | |
CN115594613B (zh) | 依度沙班中间体及其制备方法 | |
WO2003014081A1 (fr) | Procede de production d'acide azetidine-2-carboxylique optiquement actif | |
JP4263743B2 (ja) | ペリンドプリル及びその薬学的に許容し得る塩の新規な合成方法 | |
US7361757B2 (en) | Method for synthesizing esters of N-[(S)-1-carboxybutyl]-(S)-alanine and use thereof for synthesizing perindopril | |
JP4263744B2 (ja) | ペリンドプリル及びその薬学的に許容し得る塩の新規な合成方法 | |
CN112341354B (zh) | 一种pms的合成方法 | |
JPH04198175A (ja) | 光学活性アテノロール及びその中間体の製法 | |
CA2236117C (fr) | Procede d'elaboration de cyanohydrines a activite optique | |
JPH08253497A (ja) | ペプチド型化合物 | |
WO1998035934A1 (fr) | DERIVES DE η-OXO-HOMOPHENYLALANINE ET PROCEDE DE PRODUCTION DE DERIVES D'HOMOPHENYLALANINE PAR REDUCTION DE CES DERNIERS | |
JP2002265481A (ja) | 高分子担持光学活性ホスフィン化合物 | |
JPH1149750A (ja) | ピロリジン−2,4−ジオン誘導体の製法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06745226 Country of ref document: EP Kind code of ref document: A1 |